Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Tamada

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Cancer Medicine|December 2, 2022
Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR studyMasatoshi Eto, Toshio Takagi, Go Kimura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 14, 2020
Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patientsYoshihiko Tomita, Katsunori Tatsugami, Noboru Nakaigawa, et al.
International Journal of Clinical Oncology|November 20, 2021
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 studySatoshi Tamada, Chihiro Kondoh, Nobuaki Matsubara, et al.
International Journal of Clinical Oncology|September 30, 2019
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC studyTaro Iguchi, Satoshi Tamada, Minoru Kato, et al.
World Journal of Urology|September 17, 2014
Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised studyOsamu Yokoyama, Akira Tsujimura, Hironobu Akino, et al.
Japanese Journal of Clinical Oncology|January 16, 2025
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern AsiaHsiao-Jen Chung, Chihiro Kondoh, Woo Kyun Bae, et al.
The Lancet. Oncology|December 7, 2020
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThomas Powles, Elizabeth R Plimack, Denis Soulières, et al.
European Urology|July 27, 2023
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 StudyElizabeth R Plimack, Thomas Powles, Viktor Stus, et al.
European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
Nature Medicine|August 1, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trialBrian I Rini, Elizabeth R Plimack, Viktor Stus, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Cancer Medicine|December 2, 2022
Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR studyMasatoshi Eto, Toshio Takagi, Go Kimura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 14, 2020
Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patientsYoshihiko Tomita, Katsunori Tatsugami, Noboru Nakaigawa, et al.
International Journal of Clinical Oncology|November 20, 2021
Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 studySatoshi Tamada, Chihiro Kondoh, Nobuaki Matsubara, et al.
International Journal of Clinical Oncology|September 30, 2019
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC studyTaro Iguchi, Satoshi Tamada, Minoru Kato, et al.
World Journal of Urology|September 17, 2014
Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised studyOsamu Yokoyama, Akira Tsujimura, Hironobu Akino, et al.
Japanese Journal of Clinical Oncology|January 16, 2025
First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern AsiaHsiao-Jen Chung, Chihiro Kondoh, Woo Kyun Bae, et al.
The Lancet. Oncology|December 7, 2020
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThomas Powles, Elizabeth R Plimack, Denis Soulières, et al.
European Urology|July 27, 2023
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 StudyElizabeth R Plimack, Thomas Powles, Viktor Stus, et al.
European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
Nature Medicine|August 1, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trialBrian I Rini, Elizabeth R Plimack, Viktor Stus, et al.
Pageof 7